Effect of short-term treatment with sitagliptin or glibenclamide on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus

Diabetes, Obesity & Metabolism
Ryo SuzukiTakashi Kadowaki

Abstract

To compare the effect of a dipeptidyl peptidase-4 inhibitor (DPP4-i) and a sulfonylurea (SU) on daily glucose fluctuation in drug-naïve Japanese patients with type 2 diabetes mellitus (T2DM). A total of 53 drug-naïve Japanese patients with T2DM (HbA1c, 7.0%-9.0%; fasting plasma glucose, 6.1 mmol/L or higher) were randomly assigned to either sitagliptin 50 mg qd or glibenclamide 2.5 mg per day (given in divided doses) in a 1:1 ratio. A continuous glucose monitoring (CGM) device was used to obtain 24-hour glucose profiles for each patient at baseline and at Week 2. The primary study endpoint was change from baseline in mean amplitude of glucose excursion (MAGE) during a 24-hour period. A key secondary endpoint was change from baseline in the standard deviation (SD) of 24-hour glucose levels. After 2 weeks of treatment, a numerically greater reduction in MAGE from baseline was observed in the sitagliptin group compared with the glibenclamide group, but the between-treatment difference was not statistically significant (LS mean difference [95% CI]: -0.48 mmol/L [-1.31, 0.34]; P = .245). However, a significantly greater reduction in the change from baseline in SD was observed in the sitagliptin group compared with the glibenclamide ...Continue Reading

References

Aug 30, 2000·Diabetes Research and Clinical Practice·W B Wan MohamadM Mafauzy
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Louis MonnierClaude Colette
Dec 8, 2009·Endocrine Reviews·Sarah E SiegelaarJ Hans DeVries
Feb 5, 2011·Diabetes Technology & Therapeutics·Gert FritzscheEckhard Salzsieder
Apr 30, 2011·Journal of Diabetes Science and Technology·Dorota CzerwoniukWojciech Mlynarski
Apr 25, 2013·Diabetes·F John Service
May 18, 2016·Journal of Diabetes Investigation·Yutaka SeinoDaisuke Yabe
Nov 23, 2017·Diabetes Care·Thomas DanneMoshe Phillip
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.